3.8 Article

Imaging of Prostate Cancer Using Fluciclovine

Journal

PET CLINICS
Volume 12, Issue 2, Pages 145-157

Publisher

ELSEVIER INC
DOI: 10.1016/j.cpet.2016.11.005

Keywords

FACBC; Fluciclovine; Axumin; CT; PET; Prostate

Funding

  1. Emory University Office [R01CA129356, P50 CA 128301]
  2. Blue Earth Diagnostics, Ltd
  3. Nihon Medi- Physics Co, Ltd [R01CA129356, P50 CA 128301, R01 CA169188, RO1 CA156755, R21 CA176684-01]
  4. company Blue Earth Diagnostics, Ltd [NCT02680041, 118/2014/O/Oss]
  5. Emory University Office
  6. Nihon Medi-Physics Co, Ltd [R01CA129356, P50 CA 128301, R01 CA169188, R21 CA176684-01, R01 CA156755]

Ask authors/readers for more resources

Prostate cancer is the most common cancer and the second leading cause of cancer death in men in the United States. Despite high disease prevalence, diagnosis and surveillance of the disease with conventional imaging are limited typically because of indolent biology. Functional imaging with advanced molecular techniques improves the ability to detect disease. Amino acids are building blocks of proteins, and intracellular transport of amino acids is upregulated in prostate cancer. This review provides a detailed overview of the use of F-18 fluciclovine PET in prostate cancer imaging.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available